PL-BIOSCIENCE-GMBH
2.6.2023 07:23:26 CEST | Business Wire | Press release
PL BioScience GmbH, a German life science company specializing in the production and development of Human Platelet Lysate (HPL) for cell expansion, today announced a Patent License and Assignment Agreement with the French company Macopharma S.A.S. As a result of the Agreement, PL BioScience will hereby accept a worldwide license under the patents filed by Macopharma, with a right to sublicense (through multiple tiers), for the duration of the license period.
In addition to the Patent License and Assignment Agreement, Macopharma will introduce PL BioScience to their current HPL customers, and thanks to a comprehensive comparative evaluation showing equivalence of HPL products from PL BioScience, Macopharma HPL customers will have the opportunity to transfer their future orders to PL BioScience with minimal disruption.
About PL BioScience:
Located in Aachen in Germany, PL BioScience GmbH is a life science company specializing in the production and development of Human Platelet Lysate (HPL), offering a complete portfolio of HPL products tailored for various use cases; from standard laboratory research to GMP cell therapies. From academic research, pre-clinical research, and cell therapy, the high quality GMP compliant standards of ELAREM™ ensures seamless transitions of regenerative medicine breakthroughs – from the lab to patients in need.
About Macopharma
Founded in 1977, Macopharma is a major player in the medical devices industry in the blood sector. Based in Tourcoing, in the North of France (59), its development has always been driven by important innovations, results of investments made in research and development and collaborations customers and partners (blood transfusion centers, research laboratories, hospitals...). For all these activities, Macopharma offers a range of solutions that respond to each step of the process from donor to patient.
With more than 2000 employees, 3 plants (in France, Poland and Tunisia) and a presence in nearly 100 countries worldwide, Macopharma's vision is to provide sustainable products and integrated services to ensure safe and secured blood component solutions to every patient in the world.
For more information, visit macopharma.com and follow Linkedin MACOPHARMA
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230601005952/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Reply at VivaTech 2026: Making AI, Agents and Robotics Happen Across the Enterprise8.6.2026 10:00:00 CEST | Press release
Reply[EXM, STAR: REY] is taking part in VivaTech 2026, Europe's largest innovation and technology event, held from June 17 to 20 at Paris Expo Porte de Versailles. At the event, Reply will showcase its latest innovations around AI for software engineering, AI-powered experiences, data and AI, and industrial AI. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608667672/en/ At VivaTech 2026 Reply will showcase its latest innovations around AI for software engineering, AI-powered experiences, data and AI, and industrial AI. Industries are being reshaped by AI, autonomous agents, robotics and new digital experiences. From strategy to execution, Reply helps companies move beyond experimentation and innovative ideas into concrete business value. Visitors can meet Reply in Hall 7.1, booth 1G12, and explore how, through real use cases, scalable solutions and live demonstrations, the group makes innovation happen. This year, Reply'
Cardiolife Partners with Bhutan Ministry of Health to Strengthen Nationwide Cardiac Care8.6.2026 10:00:00 CEST | Press release
Cardiolife is proud to partner with the Ministry of Health of Bhutan to roll out its advanced AI-powered ECG diagnostics system nationwide. The collaboration will provide access to early ECG diagnosis and prevention, marking a major step forward in the country’s effort to strengthen heart health and preventive care. Bhutan has a population of just over 700,000 people and heart failure and other cardiac conditionsare among the leading causes of death. Following constructive meetings in Thimphu, His Excellency, the Health Minister, officially endorsed the national rollout of Cardiolife’s solution and expressed appreciation for Cardiolife’s commitment to advancing cardiac care through the provision of free software and ECG equipment in Bhutan. “We are grateful to the Cardiolife team for their commitment to improving heart health in Bhutan. With cardiovascular diseases on the rise, this collaboration marks an important milestone in our journey to strengthen early detection and prevention a
Cegid Closes Acquisition of Shine to Create Europe's First Complete AI-Driven Platform for SMBs and Accountants8.6.2026 09:28:00 CEST | Press release
Accelerates Cegid’s trajectory to become the leading European financial solutions hub integrating e-invoicing, accounting, digital finance, payment services and accounts, and HR solutionsTransaction supported by new €1.1 billion debt financing facility secured from leading direct credit funds, underscoring Cegid’s strong business performance and unique leadership positioning in rapidly evolving software sector Cegid, a European leader in cloud management solutions for professionals in the finance (treasury, tax, ERP), human resources (payroll, talent management), accountancy, retail and entrepreneurship sectors, today announced the completion of its acquisition of Shine. The transaction creates the first fully integrated, cloud-native and AI-driven financial hub for SMBs and accounting professionals in Europe. Shine – a fast-growing European fintech unicorn providing electronic invoicing, accounting, business accounts, and payroll software to small and medium-sized businesses across Eu
ARIS Announced as Exclusive Process Intelligence Launch Partner for AWS European Sovereign Cloud8.6.2026 09:00:00 CEST | Press release
Partnership Will Enable Enterprises to Accelerate AI Adoption While Ensuring Digital Sovereignty ARIS, the process context foundation for enterprise AI deployment, today announced its collaboration with Amazon Web Services (AWS) to support organizations navigating increasingly complex digital sovereignty requirements while accelerating AI-driven transformation. Many European enterprises face growing pressure to ensure sensitive operational and business data remains under European governance and regulatory control. Through the AWS European Sovereign Cloud (ESC), they will be able to combine advanced cloud and AI capabilities with enhanced operational separation, EU-based governance, and strict data residency controls. ARIS will support customers looking to operationalize AI safely and at scale within these boundaries by providing the process intelligence, governance, and operational context required for trusted enterprise AI deployment. “AI is moving rapidly from experimentation to oper
Cosylab Launches PlanOne™ Treatment Planning System for Particle Therapy8.6.2026 08:00:00 CEST | Press release
Cosylab today announced the commercial launch of PlanOne™, a treatment planning system for particle therapy, bringing physics-accurate, radiobiologically informed planning and a unified clinical workflow into a single environment. PlanOne™ is FDA 510(k) cleared. "PlanOne™ began with listening. Over the years, our work on control systems in radiation oncology has put us in direct, ongoing contact with medical physicists and clinical teams at some of the leading facilities in the world," said Mark Pleško, CEO of Cosylab. "Our partners have been clear on what matters most for particle therapy: physics accuracy they can defend, clinical confidence at the point of plan approval, and a platform built to grow with AI and adaptive workflows. We designed PlanOne™ around those three priorities, and we'll keep developing it together with the clinical community that helped shape it." Physics-accurate, radiobiologically informed planning PlanOne™ is built on a GPU-accelerated Monte Carlo dose engin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom